KEVIN GAREY to Tetracyclines
This is a "connection" page, showing publications KEVIN GAREY has written about Tetracyclines.
Connection Strength
2.376
-
Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial. J Antimicrob Chemother. 2025 Oct 03; 80(10):2719-2726.
Score: 0.956
-
Phase I trial comparing bile acid and short-chain fatty acid alterations in stool collected from human subjects treated with omadacycline or vancomycin. Antimicrob Agents Chemother. 2025 02 13; 69(2):e0125124.
Score: 0.910
-
Development and validation of LC-MS/MS for quantifying omadacycline from stool for gut microbiome studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Apr 01; 1236:124057.
Score: 0.214
-
Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers. J Infect Dis. 2024 01 12; 229(1):273-281.
Score: 0.212
-
In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. J Antimicrob Chemother. 2020 10 01; 75(10):2879-2884.
Score: 0.042
-
In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile. Antimicrob Agents Chemother. 2020 07 22; 64(8).
Score: 0.042